TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21820424
Drug: Propylthiouracil (PTU)
Normalized name: Propylthiouracil
DrugBank: Propylthiouracil (DB00550)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propylthiouracil (PTU) treatment
Study: 22784254
Drug: MMI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMI treatment
Study: 17575805
Drug: Highly purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly purified omega-3 polyunsaturated fatty acids (PUFAs) at a dose of 1 g/day
Study: 17575805
Drug: Standard secondary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard secondary pharmacological prevention therapy (anti-platelet agents, statins, beta-blockers, ACE inhibitors)
Study: 10894877
Drug: Daniplestim (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daniplestim (2.5 microgram/kg/d) plus G-CSF (10 microgram/kg/d)
Study: 10894877
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus G-CSF (10 microgram/kg/d)
Study: 8931033
Drug: Calcium citrate
Normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium citrate solution (500 mg Ca2+)
Study: 8931033
Drug: Calcium lactogluconate/carbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium lactogluconate/carbonate solution (500 mg Ca2+)
Study: 8931033
Drug: Calcium citrate
Normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium citrate suspension (500 mg Ca2+)
Study: 3917619
Drug: Active surveillance
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active surveillance (weekly telephone contact)
Study: 30328956
Drug: CBD 150
Normalized name: CBD
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBD 150 mg
Study: 27776675
Drug: Problem Recognition
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem Recognition Questionnaire (PRQ) pre-treatment
Study: 27776675
Drug: Problem Recognition
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem Recognition Questionnaire (PRQ) post-treatment
Study: 17913408
Drug: Soy isoflavone
Normalized name: soy isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavone extract (250 mg of standardized soy extract, total of 100 mg/day of isoflavone)
Study: 15643102
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg fluoxetine capsules administered rectally
Study: 15643102
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg fluoxetine capsules administered orally
Study: 15643102
Drug: Rectal route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal route of administration
Study: 11788642
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral dexamethasone test
Study: 11788642
Drug: 0.0035 mg
Normalized name: menthol 0.0035 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0035 mg oral dexamethasone per kg
Study: 11788642
Drug: 0.0070 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0070 mg oral dexamethasone per kg
Study: 11788642
Drug: 0.015 mg
Normalized name: sulfur 0.015 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.015 mg oral dexamethasone per kg
Study: 11788642
Drug: All variable-dose
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All variable-dose tests
Study: 10784385
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil diet (80 g of corn oil, 20 mg alpha‐tocopherol, 100 mg gamma‐tocopherol)
Study: 10784385
Drug: Olive/sunflower oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive/sunflower oil diet (80 g of olive/sunflower oil, 24 mg alpha‐tocopherol, 2.4 mg gamma‐tocopherol)
Study: 7746909
Drug: Salbutamol powder
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol powder (1.6 mg) from the Diskhaler
Study: 7746909
Drug: Salbutamol nebulizer
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol nebulizer solution (2.5 ml, 1 mg ml‐1) from a jet nebulizer
Study: 6785790
Drug: Chlorpromazine (CPZ)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine (CPZ) at fixed doses (200, 400, or 600 mg)
Study: 23420053
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (stapling/suturing)
Study: 8393637
Drug: Atrial Natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial Natriuretic Peptide (ANP) infusion at 5 ng/kg/min
Study: 8393637
Drug: Atrial Natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial Natriuretic Peptide (ANP) infusion
Study: 2947777
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg DMPA
Study: 2947777
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg DMPA
Study: 20123224
Drug: Oxygen supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen supplementation at 2 L/min via nasal cannulae overnight
Study: 16363902
Drug: Balloon Angioplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon Angioplasty with adjunctive endovascular brachytherapy (BA+EVBT)
Study: 12225549
Drug: Postnatal MgSO(4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postnatal MgSO(4) infusion (250 mg/kg per day) for 3 days
Study: 12225549
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no MgSO(4) infusion)
Study: 7883833
Drug: Desipramine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (75 mg, orally)
Study: 25738891
Drug: Web-based counselor-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based counselor-assisted family problem-solving therapy (CAPS)
Study: 11850141
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide (active doses)
Study: 11850141
Drug: No-drug option
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-drug option
Study: 28225313
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel 2% (Tgel) 23 mg/day, uptitrated to 46 mg/day after 2 weeks if necessary, with further adjustments possible on Days 21, 42, and 63.
Study: 28225313
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel 2% (Tgel)
Study: 21813914
Drug: Lactate (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate (120 mg/kg body mass)
Study: 19114909
Drug: Furosemide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (0.5 mg/kg/hr)
Study: 15837997
Drug: BMS‐275291, 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐275291, 1,200 mg orally daily
Study: 7605852
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg b.d. for 4 weeks
Study: 7605852
Drug: Etodolac 400
Normalized name: etodolac 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 400 mg b.d. for 4 weeks
Study: 378040
Drug: Triprolidine 2.5
Normalized name: triprolidine 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triprolidine 2.5 mg t.i.d.
Study: 378040
Drug: Triprolidine 1.25
Normalized name: TRIPROLIDINE 1.25MG/5ML ORAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triprolidine 1.25 mg t.i.d.
Study: 30565155
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg enteric-coated aspirin once daily
Study: 28207724
Drug: Green Prescription
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green Prescription plus Kia Ākina (KA/GRx)
Study: 28207724
Drug: Green Prescription
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green Prescription alone (GRx)
Study: 14739148
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B lipid complex (ABLC) 3 mg/kg/day every 21 days
Study: 11465701
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (1 mg/day)
Study: 11465701
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid (2.5 mg/week)
Study: 11465701
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (1 mg/day) and Folinic acid (2.5 mg/week)
Study: 8067370
Drug: Oral support
Normalized name: MTX Support Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral support
Study: 8067370
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral support
Study: 20184572
Drug: L-carnitine (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (group C)
Study: 14507127
Drug: Kinetic cavity
Normalized name: Kineticream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinetic cavity preparation (KCP)
Study: 10090440
Drug: Antihistamines (fexofenadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamines (fexofenadine or loratadine) for 2 weeks after 1 week of placebo
Study: 8525693
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination with inactivated uropathogenic bacteria (Solco‐Urovac)
Study: 2180234
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules
Study: 2180234
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of Ty21a Salmonella typhi vaccine in enteric-coated capsules
Study: 2180234
Drug: Ty21a Salmonella
Normalized name: Salmonella typhi Ty21a live antigen
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ty21a Salmonella typhi vaccine (both doses)
Study: 548940
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cefaclor orally
Study: 548940
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cephalexin orally
Study: 548940
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g cefaclor orally 4 times daily
Study: 548940
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cefaclor (single dose)
Study: 27724923
Drug: Daily probiotics
Normalized name: Digestive Advantage Daily Probiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily probiotics (four capsules of Vivomixx®; total of 450 billion CFU/day)
Study: 23964444
Drug: NSAIDs (diclofenac)
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSAIDs (diclofenac) 75 mg/d with curcumin 1,000 mg/d for 3 months
Study: 23964444
Drug: NSAIDs (diclofenac)
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSAIDs (diclofenac) 75 mg/d with placebo
Study: 17657838
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy of lafutidine, clarithromycin, and amoxicillin
Study: 17657838
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy of lansoprazole, clarithromycin, and amoxicillin
Study: 15309484
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with verteporfin
Study: 11792748
Drug: HPV testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV testing at 1.0 pg/mL threshold for ASCUS
Study: 11792748
Drug: HPV testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV testing at 10.0 pg/mL threshold for ASCUS
Study: 6531969
Drug: RA 27/3
Normalized name: Rubivirus rubella virus Wistar RA 27/3 whole
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA 27/3 strain rubella vaccine (Rudivax)
Study: 30288156
Drug: FDC tablet
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablet (gemigliptin/metformin SR 50/1,000 mg)
Study: 30288156
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of individual tablets (gemigliptin 50 mg and metformin XR 1,000 mg)
Study: 27650124
Drug: ω‐3 polyunsaturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 polyunsaturated fatty acids (PUFAs) treatment for 12 weeks
Study: 25379431
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (ATX) administration
Study: 20088695
Drug: 12-week treatment
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week treatment
Study: 16956917
Drug: 24-week treatment
Normalized name: Weeks and Leo Complete Lice Treatment KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-week treatment
Study: 20088695
Drug: Suboptimal drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suboptimal drug concentrations
Study: 18852484
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of Ascorbic Acid (AA)
Study: 18852484
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of iron carbonyl
Study: 18852484
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of Ascorbic Acid (AA) plus 150 mg of iron carbonyl
Study: 15733070
Drug: High-dose glucose-insulin-potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose glucose-insulin-potassium (GIK) treatment for 24 hours
Study: 15733070
Drug: High-dose glucose-insulin-potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose glucose-insulin-potassium (GIK) treatment
Study: 10664047
Drug: Latanoprost, 0.005%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost, 0.005% once daily
Study: 10664047
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of timolol, 0.5% twice daily, and dorzolamide, 2% twice daily
Study: 1539069
Drug: Acetaminophen (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (0, 325, 650, 1300 or 1950 mg)
Study: 1539069
Drug: Ethanol (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (total dose = 0.625 g/kg; five divided doses)
Study: 24842476
Drug: CZP 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 200 mg and methotrexate (J-RAPID trial)
Study: 24842476
Drug: CZP 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 200 mg alone or with disease-modifying agents other than methotrexate (HIKARI trial)
Study: 19179968
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2b monotherapy
Study: 17517832
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2b plus lamivudine combination therapy
Study: 11481357
Drug: ADocT (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADocT (doxorubicin 50 mg/m2 and docetaxel 75 mg/m2 with tamoxifen)
Study: 11481357
Drug: ADoc (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADoc (doxorubicin 50 mg/m2 and docetaxel 75 mg/m2 without tamoxifen)
Study: 9707742
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg in children or 500 mg/day in adults for 3 days)
Study: 9707742
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid (standard doses for 7 to 14 days)
Study: 9707742
Drug: Cefaclor (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (standard doses for 7 to 14 days)
Study: 3133266
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + Glibenclamide (15 mg per day)
Study: 22590838
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + Placebo
Study: 26042933
Drug: Lomustine single
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lomustine single agent
Study: 26042933
Drug: Bevacizumab single
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab single agent
Study: 12526280
Drug: Telmisartan 40-80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40-80 mg
Study: 16421476
Drug: Losartan 50-100
Normalized name: losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan 50-100 mg
Study: 11320384
Drug: Melatonin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (2 mg)
Study: 17462454
Drug: Antifibrinolytic drugs
Normalized name: ANTIFIBRINOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifibrinolytic drugs
Study: 29518295
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (1.0 ml) and injectable water (1.5 ml)
Study: 29518295
Drug: Bupivacaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (1 ml, 5 mg/ml) and injectable water (1.5 ml)
Study: 17596110
Drug: Darunavir/r (400/100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/r (400/100mg twice daily)
Study: 17596110
Drug: Atazanavir/r (300/100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/r (300/100mg once daily)
Study: 17596110
Drug: Darunavir/r (400/100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/r (400/100mg twice daily) plus Atazanavir (300mg once daily)
Study: 16334443
Drug: Antibiotic combination
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic combination therapy (amoxicillin, tetracycline, metronidazole) for 2 weeks
Study: 346192
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy (Vinblastin 6 mg/m2, Thiotepa 6 mg/m2, Rufocromomycine 60 microgram/m2, Methotrexate 15 mg/m2, Procarbazine 30 mg/m2)
Study: 346192
Drug: Intraarterial chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial chemotherapy (DTIC 80 mg/kg for ten days)
Study: 24239156
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg/daily for 30 days
Study: 24239156
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg/daily for 30 days
Study: 24239156
Drug: Bergamot-derived polyphenolic
Normalized name: BERGAMOT
DrugBank: Bergamot oil (DB14335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bergamot-derived polyphenolic fraction (BPF) 1000 mg/daily for 30 days
Study: 24239156
Drug: BPF 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPF 1000 mg/daily plus rosuvastatin 10 mg/daily for 30 days
Study: 18649820
Drug: Programmable medication
Normalized name: PUMP,LUTREPULSE PROGRAMMABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmable medication devices (dispensers and timers)
Study: 15248415
Drug: Intravenous amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amoxicillin plus clavulanic acid (2.2 g) administered 10 minutes before tonsillectomy
Study: 15248415
Drug: Oral amoxicillin-clavulanic
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin-clavulanic acid (3 doses the day before surgery, plus one oral administration 2 hours before tonsillectomy)
Study: 11086366
Drug: Stratified care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratified care (n = 279) with aspirin 800 to 1000 mg plus metoclopramide 10 mg for MIDAS grade II and zolmitriptan 2.5 mg for MIDAS grade III and IV.
Study: 11086366
Drug: Step care
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step care across attacks (n = 271) with initial treatment of aspirin 800 to 1000 mg plus metoclopramide 10 mg, switching to zolmitriptan 2.5 mg if not responding in at least 2 of the first 3 attacks.
Study: 11086366
Drug: Step care
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step care within attacks (n = 285) with initial treatment of aspirin 800 to 1000 mg plus metoclopramide 20 mg, escalating to zolmitriptan 2.5 mg if not responding after 2 hours.
Study: 8442969
Drug: Succinylcholine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 0.5 mg/kg after no pretreatment
Study: 8442969
Drug: Succinylcholine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 0.5 mg/kg after d‐tubocurarine 0.05 mg/kg IV 3 minutes before
Study: 8442969
Drug: Succinylcholine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 0.5 mg/kg after chlorpromazine 0.1 mg/kg IV 3 minutes before
Study: 8442969
Drug: Succinylcholine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 0.5 mg/kg after alpha‐tocopherol (vitamin E) 600 mg in three divided doses orally at 6‐hour intervals
Study: 8442969
Drug: Succinylcholine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 0.5 mg/kg after aspirin 600 mg orally 1 hour before
Study: 31678224
Drug: Local consolidative
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local consolidative therapy (LCT)
Study: 28549873
Drug: Topical Betadine
Normalized name: Betadine Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Betadine (Povidone‐iodine)
Study: 28549873
Drug: Topical Clotrimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Clotrimazole
Study: 16515902
Drug: Heparin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin with protamine reversal